Evidence map›Paper›PMID 39384409›Full record

ReviewThe Journal of neuroscience : the official journal of the Society for Neuroscience2024

Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?

Joia K Capocchi, Claudia Figueroa-Romero, Sage J B Dunham, Gina Faraci, Jason A Rothman, Katrine L Whiteson, Dong-Oh Seo, David M Holtzman, Stefanie Grabrucker, Yvonne M Nolan and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joia K CapocchiUniversity of California, Irvine, Irvine, California 92697.ORCID 0000-0002-3433-5904
Claudia Figueroa-RomeroNational Institute of Neurological Disorders and Stroke, Rockville, Maryland 20852.ORCID 0000-0001-7546-4190
Sage J B DunhamUniversity of California, Irvine, Irvine, California 92697.ORCID 0000-0002-6338-5038
Gina FaraciUniversity of California, Irvine, Irvine, California 92697.ORCID 0000-0003-2789-7383
Jason A RothmanUniversity of California, Irvine, Irvine, California 92697.ORCID 0000-0002-4848-8901
Katrine L WhitesonUniversity of California, Irvine, Irvine, California 92697.ORCID 0000-0002-5423-6014
Dong-Oh SeoWashington University School of Medicine in St. Louis, St. Louis, Missouri 63110.ORCID 0000-0003-0315-4489
David M HoltzmanWashington University School of Medicine in St. Louis, St. Louis, Missouri 63110.ORCID 0000-0002-3400-0856
Stefanie GrabruckerDepartment of Anatomy and Neuroscience, University College Cork, Cork T12 XF62, Ireland.
Yvonne M NolanDepartment of Anatomy and Neuroscience, University College Cork, Cork T12 XF62, Ireland.ORCID 0000-0003-2426-234X
Rima Kaddurah-DaoukDuke University School of Medicine, Durham, North Carolina 27710.
David A JettNational Institute of Neurological Disorders and Stroke, Rockville, Maryland 20852 jettd@ninds.nih.gov.ORCID 0000-0002-8064-6690

Funding

UC Irvine MODEL-ADU54AG054349 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Kim Green · 2017 to 2026
$71.9M
Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Training in the Neurobiology of Aging and Alzheimers DiseaseT32AG000096 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI VIVEK SWARUP, Craig E Stark · 1985 to 2026
$9.6M
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type DementiasRF1AG051550 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KLING, MITCHEL ALLAN · 2015 to 2016
$6.3M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's DiseaseRF1AG057452 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2017 to 2017
$3.5M
Gut Liver Brain Biochemical Axis in Alzheimer's DiseaseRF1AG058942 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, VAN DUIJN, CORNELIA MARJA · 2018 to 2018
$3.4M
OLDER ESRD PATIENTS: REHABILITATION &QUALITY OF LIFER01AG005909 · NIA · EMORY UNIVERSITY · PI KUTNER, NANCY G · 1987 to 1989
–
NIA NIH HHS R01 AG005909NIA NIH HHS R01 AG046171NIA NIH HHS RF1 AG051550NIA NIH HHS RF1 AG057452NIA NIH HHS RF1 AG058942NIA NIH HHS T32 AG000096NIA NIH HHS U01 AG061359NIA NIH HHS U19 AG063744NIA NIH HHS U54 AG054349
6 · The paper itself

Abstract

Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRDs) are broad-impact multifactorial neurodegenerative diseases. Their complexity presents unique challenges for developing effective therapies. This review highlights research presented at the 2024 Society for Neuroscience meeting which emphasized the gut microbiome's role in AD pathogenesis by influencing brain function and neurodegeneration through the microbiota-gut-brain axis. This emerging evidence underscores the potential for targeting the gut microbiota to treat AD/ADRD.

Indexed as

Alzheimer DiseaseGastrointestinal MicrobiomeAnimalsBrainBrain-Gut AxisDementiaHumans

Identifiers

PMID39384409
PMCPMC11466070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.